Henry Schein (HSIC) Received its Third Buy in a Row


After Guggenheim and Craig-Hallum gave Henry Schein (NASDAQ: HSIC) a Buy rating last month, the company received another Buy, this time from Barrington. Analyst Michael Petusky maintained a Buy rating on Henry Schein today and set a price target of $75. The company’s shares opened today at $67.04.

Petusky said:

“We continue to rate HSIC shares an OUTPERFORM and are increasing our price target to $75 from $72 previously. We arrive at our price target by attaching a 13x multiple to our 2019 adjusted EBITDA estimate. We assume $1.1 billion in net debt 12 months from now.”

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.1% and a 53.3% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $67.43, a 0.6% upside from current levels. In a report released today, Craig-Hallum also reiterated a Buy rating on the stock with a $77 price target.

See today’s analyst top recommended stocks >>

Henry Schein’s market cap is currently $10.1B and has a P/E ratio of 19.14. The company has a Price to Book ratio of 3.41.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts